Fecal microbiota transplantation for Clostridioides difficile infection in a peritoneal dialysis patient: A case report.

IF 2.7 3区 医学 Q2 UROLOGY & NEPHROLOGY
Giovanni Marasco, Daniela Cecilia Cannarile, Cesare Cremon, Giuliana Papalia, Antonella Marangoni, Annalisa Zucchelli, Monica Barone, Tiziana Lazzarotto, Patrizia Brigidi, Vincenzo Stanghellini, Giovanni Barbara
{"title":"Fecal microbiota transplantation for <i>Clostridioides difficile</i> infection in a peritoneal dialysis patient: A case report.","authors":"Giovanni Marasco, Daniela Cecilia Cannarile, Cesare Cremon, Giuliana Papalia, Antonella Marangoni, Annalisa Zucchelli, Monica Barone, Tiziana Lazzarotto, Patrizia Brigidi, Vincenzo Stanghellini, Giovanni Barbara","doi":"10.1177/08968608251316165","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic kidney disease (CKD) may be associated with dysbiosis which may increase the risk of gastrointestinal infections. Patients with kidney failure have a predominance of bacteria responsible for the exacerbation of chronic inflammation through the production of ureases, uricase, and uremic toxins and a reduction of bacteria-producing protective molecules as short-chain fatty acids. Patients with CKD have an increased risk of <i>Clostridioides difficile</i> infection. Currently, besides antibiotic therapy, fecal microbiota transplantation (FMT) is the only effective gut microbiota-targeted therapy for treating this infection. Scant evidence is available on FMT in those receiving peritoneal dialysis (PD). In this case, we report a successful FMT performed by colonoscopy in a patient receiving PD for polycystic kidney disease suffering from recurrent <i>Clostridioides difficile</i> infections. The FMT was repeated to enhance microbiota engraftment. The role of FMT in treating <i>Clostridioides difficile</i> in individuals receiving PD may be an important and promising therapeutic strategy but requires further prospective study.</p>","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251316165"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peritoneal Dialysis International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08968608251316165","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic kidney disease (CKD) may be associated with dysbiosis which may increase the risk of gastrointestinal infections. Patients with kidney failure have a predominance of bacteria responsible for the exacerbation of chronic inflammation through the production of ureases, uricase, and uremic toxins and a reduction of bacteria-producing protective molecules as short-chain fatty acids. Patients with CKD have an increased risk of Clostridioides difficile infection. Currently, besides antibiotic therapy, fecal microbiota transplantation (FMT) is the only effective gut microbiota-targeted therapy for treating this infection. Scant evidence is available on FMT in those receiving peritoneal dialysis (PD). In this case, we report a successful FMT performed by colonoscopy in a patient receiving PD for polycystic kidney disease suffering from recurrent Clostridioides difficile infections. The FMT was repeated to enhance microbiota engraftment. The role of FMT in treating Clostridioides difficile in individuals receiving PD may be an important and promising therapeutic strategy but requires further prospective study.

粪便菌群移植治疗腹膜透析患者难辨梭菌感染1例。
慢性肾脏疾病(CKD)可能与生态失调有关,这可能增加胃肠道感染的风险。肾衰竭患者有优势的细菌,通过产生脲酶、尿酸酶和尿毒症毒素,减少细菌产生的保护分子,如短链脂肪酸,导致慢性炎症恶化。CKD患者难辨梭菌感染的风险增加。目前,除了抗生素治疗外,粪便微生物群移植(FMT)是治疗这种感染的唯一有效的肠道微生物群靶向治疗方法。在接受腹膜透析(PD)的患者中,FMT的证据很少。在这种情况下,我们报告了一个成功的FMT结肠镜下的病人接受PD多囊肾病复发艰难梭菌感染。重复FMT以增强微生物群的植入。FMT在治疗PD患者难辨梭菌中的作用可能是一种重要且有前途的治疗策略,但需要进一步的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Peritoneal Dialysis International
Peritoneal Dialysis International 医学-泌尿学与肾脏学
CiteScore
6.00
自引率
17.90%
发文量
69
审稿时长
6-12 weeks
期刊介绍: Peritoneal Dialysis International (PDI) is an international publication dedicated to peritoneal dialysis. PDI welcomes original contributions dealing with all aspects of peritoneal dialysis from scientists working in the peritoneal dialysis field around the world. Peritoneal Dialysis International is included in Index Medicus and indexed in Current Contents/Clinical Practice, the Science Citation Index, and Excerpta Medica (Nephrology/Urology Core Journal). It is also abstracted and indexed in Chemical Abstracts (CA), as well as being indexed in Embase as a priority journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信